BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.

Key facts

Study ID

NCT00061880

Run by

BioCryst Pharmaceuticals

Starts

2003-02-01

Expected to finish

2008-01-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.